GlassScriptPhysician profile
Muhammad Zafar
NPI 1811985856
$1,953.73
in general payments reported to CMS, 2019-2025
20 companies · $46.22 in 2025
The $46.22 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.72 · 2021: $572 · 2022: $676 · 2023: $209 · 2024: $438 · 2025: $46.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $489 · Food and Beverage: $204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $488.97 |
| Food and Beverage | $204.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $583.54 | 2021-2024 | Verzenio |
| Incyte Corporation | $299.89 | 2021-2024 | |
| Amgen INC. | $197.56 | 2021-2025 | Lumakras |
| Davol INC. | $176.04 | 2022 | |
| Axonics, INC. | $111.11 | 2022 | |
| Medical Device Business Services, INC. | $101.31 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $99.95 | 2021 | |
| Conmed Corporation | $71.43 | 2022 | |
| Intuitive Surgical, INC. | $62.50 | 2022 | |
| Novartis Pharmaceuticals Corporation | $47.38 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $45.67 | 2021-2024 | Keytruda |
| Cti Biopharma Corp. | $32.60 | 2023 | Vonjo |
| Glaxosmithkline, LLC. | $27.07 | 2023 | Ojjaara |
| Tempus Ai, INC | $22.23 | 2024 | |
| Exelixis INC. | $17.00 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $16.99 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.45 | 2024 | Fruzaqla |
| Teva Pharmaceuticals USA, INC. | $13.50 | 2025 | Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $12.72 | 2019 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Zafar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.